

Letter to the Editor: New Observation

Transient Headache and Neurological Deficits with Cerebrospinal Fluid Lymphocytosis following COVID-19

Sina Marzoughi , Alyson Plecash and Tychicus Chen 

Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

Keywords: Headache; Infectious diseases; COVID-19

Headache is a common symptom of coronavirus disease 2019 (COVID-19) during and after infection.^{1,2} The syndrome of headache and neurologic deficit with cerebrospinal fluid lymphocytosis (HaNDL) is a unique phenotype commonly associated with viral infection but with only one case reported following COVID-19 infection to date.³ We report a second case and an approach to patients presenting with headache and focal neurological symptoms after COVID-19 (Figure 1).

A 27-year-old non-obese woman with a history of migraine without aura for over 10 years, developed new headaches 3 weeks

following a mild COVID-19 infection. She also had a recent history of acne, and depression, managed on bupropion and isotretinoin for the last 6 months. Over 2 weeks, she developed increasing holocranial, mixed pressure and throbbing, headaches lasting 5–120 minutes, occurring up to 6 times per day, without provocation. There was associated photophobia, phonophobia, nausea, and occasional vomiting. These episodes were more severe and frequent than her typical migraines, and she had never had any visual or somatosensory aura previously. Twice, she experienced migratory hemibody paresthesias following headache; the first involved




Figure 1: Approach to persistent headache following COVID-19. Red flags for secondary headaches adapted from the SNNOP10 list⁴. CSF = cerebrospinal fluid; HaNDL = headache and neurologic deficit with cerebrospinal fluid lymphocytosis.

Corresponding author: Tychicus Chen; Email: tychicus@mail.ubc.ca

Cite this article: Marzoughi S, Plecash A, and Chen T. (2024) Transient Headache and Neurological Deficits with Cerebrospinal Fluid Lymphocytosis following COVID-19. *The Canadian Journal of Neurological Sciences* 51: 444–446, <https://doi.org/10.1017/cjn.2023.51>

© The Author(s), 2023. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

Table 1: Cerebrospinal fluid results

	Day 1	Day 4
Appearance	Clear, colorless	Clear, colorless
Volume removed	8 ml	16 ml
Opening pressure (cmH ₂ O)	28	20.5
White cells (cells/uL; ref 0–5)	44	31
Lymphocytes	> 90%	> 90%
Erythrocytes (cells/uL; ref 0–5)	None	None
Xanthochromia	Absent	Absent
Protein (g/L; ref 0.15–0.45)	0.72	0.60
Glucose (mmol/L; ref 2.3–4.1)	3.4	4.0
Bacterial culture	Negative	Negative
Viral PCR (HSV1, HSV2, VZV, enterovirus)	Negative	–
Cryptococcal antigen	Negative	–
Fungal culture	Negative	Negative
AFB	Negative	Negative
Cytology	–	No abnormal cells
Flow cytometry	–	Negative

HSV = Herpes simplex virus; PCR = polymerase chain reaction; VZV = varicella zoster virus.

spread from the perioral region down the right hemibody over 30 minutes lasting a few hours, the second down the left side. The initially intermittent headaches became persistent with waxing and waning intensity and variable positional features (initially improved and later in the course worse when supine). She denied transient visual obscurations, diplopia, or pulsatile tinnitus. She presented to two separate community hospitals and both times were treated with IV fluids, ketorolac, and metoclopramide with minimal benefit. Sumatriptan, metoclopramide, and ibuprofen were prescribed but provided no pain relief. Urgent outpatient neurology opinion was requested.

Examination showed no meningismus or fever. She was alert and oriented with fluent speech. Severe photophobia made pupil and fundoscopic examination challenging although there did not appear to be papilledema. Visual acuity was 20/20 in each eye, with full visual fields. The remainder of the neurological examination was unremarkable. Given several red flag features, she was admitted to hospital for urgent investigation. Isotretinoin was discontinued.

Noncontrast head computed tomography (CT) and multiphase CT angiogram head and neck showed no intracranial mass, venous thrombosis, or vascular irregularities (beading, vasospasm, or dissection). Lumbar puncture (LP) demonstrated elevated opening pressure (28 cmH₂O), lymphocytic pleocytosis (44 cells/uL; reference 0–5), and elevated protein, but negative infectious studies (Table 1). Repeat LP 3 days later revealed improvement in opening pressure (20 cmH₂O) and lymphocytosis (Table 1). Cytology and flow cytometry showed no abnormal or malignant cells. Her headache did not improve significantly immediately following either lumbar puncture. Magnetic resonance imaging (MRI) of the brain and spinal cord with gadolinium was normal. Optical coherence tomography and automated perimetry were normal. Her course and investigations were felt to be in keeping with HaNDL

Table 2: ICHD-3 diagnostic criteria for HaNDL

A. Episodes of migraine-like headache fulfilling criteria B and C
B. Both of the following:
1. accompanied or shortly preceded by onset of at least one of the following transient neurological deficits lasting > 4 hours
a) hemiparesis
b) dysphasia
c) hemiparesis
2. associated with cerebrospinal fluid (CSF) lymphocytic pleocytosis (>15 white cells per μ l), with negative etiological studies
C. Evidence of causation demonstrated by either or both of the following:
1. headache and transient neurological deficits have developed or significantly worsened in temporal relation to onset or worsening of the CSF lymphocytic pleocytosis, or led to its discovery
2. headache and transient neurological deficits have significantly improved in parallel with improvement in the CSF lymphocytic pleocytosis
D. Not better accounted for by another ICHD-3 diagnosis.

ICHD-3 = International Classification of Headache Disorders, 3rd edition; IHS = from the International Headache Society.

(Table 2). After 6 weeks, her headaches had gradually resolved with symptomatic treatment, and there was no recurrence of transient neurologic symptoms.

HaNDL, also known as migraine with cerebrospinal pleocytosis or pseudomigraine with lymphocytic pleocytosis, presents as a constellation of self-limited migraine-like headaches, neurological symptoms, and CSF lymphocytosis.⁵ Headaches resemble migraines (often moderate to severe, throbbing, unilateral or bilateral, lasting hours, with nausea, vomiting, and photophobia) occurring in association with neurological symptoms (most commonly hemiparesis, followed by hemiparesis or dysphasia, and rarely positive visual phenomena) typically lasting from 15 minutes to 120 hours or longer.^{5,6} The course may be monophasic, but often repeated attacks occur over weeks to months.⁵ A preceding viral illness has been associated with 25%–40% of cases,⁶ often up to 3 weeks prior to the development of neurological symptoms. Active infection (i.e. chronic fungal or viral meningitis) requires exclusion with negative viral, bacterial, and fungal studies in serum and CSF. Antibodies against a subunit of T-type voltage-gated calcium channels have been found in some cases, supporting an autoimmune or inflammatory mechanism.⁷ CSF lymphocytosis ranges from 10 to 760 cells/uL (mean 199), while elevated protein and opening pressure may also be seen.⁶ Neuroimaging is generally normal in HaNDL but remains important in excluding structural causes of headache and focal neurological symptoms (mass lesion, hydrocephalus, cerebral edema, leptomeningeal inflammation, infarct, hemorrhage) or vascular abnormality (aneurysm, vasoconstriction, or cerebral venous sinus thrombosis). Treatment is supportive along with patient education and expectant management for this self-limited condition.

Idiopathic intracranial hypertension (IIH) was also considered in our case, given isotretinoin exposure and elevated opening pressure. However, IIH symptomatology generally develops soon after isotretinoin exposure (mean time to diagnosis 2.3 months) and resolves gradually over weeks to months with medication discontinuation.⁸ Our patient had been on isotretinoin for 6 months, and symptoms seemed to resolve fairly quickly, with documented normalization of CSF opening pressure on repeat LP within days. Additionally, she had tolerated longer courses of isotretinoin previously. CSF composition in IIH should be normal, and rare cases that report lymphocytosis are often seen in association with papilledema and vision loss

requiring treatment with acetazolamide or shunting.⁹ There were no neuro-ophthalmologic or neuroimaging features in our case to suggest IIH. There have been rare reports of IIH associated with COVID-19 occurring during active infection but again with normal CSF composition.¹⁰

To date, there is only one other report of HaNDL following COVID-19 infection.³ Headache is a common symptom of both active COVID-19 infection and in the postinfectious period,^{1,2} with several proposed mechanisms including inflammation, cytokine release, endothelial dysfunction, raised intracranial pressure, and venous congestion.^{1,10} The absence of detectable virus in inflammatory CSF of patients with neurological symptoms supports an indirect autoimmune mechanism.² Furthermore, the timing of symptom onset in our case 3 weeks following infection would support a postinfectious hypothesis as described in other cases of HaNDL.⁶ It is proposed that viral infection could trigger activation of the immune system, producing antibodies to antigens in cranial vessels and aseptic inflammation accounting for headaches and CSF lymphocytosis, and transient cerebral hypoperfusion leading to neurological symptoms.⁶ This is also reflective of the often-monophasic course, with resolution within 3 months, also seen in our case. The most common chronic headache phenotypes following COVID-19 are migraine or tension,^{11,12} which may be part of a wider spectrum of the so-called “long-Covid syndrome” which can also include fatigue, rash, respiratory symptoms, and mental health and cognitive symptoms including anxiety, depression, and insomnia. A monophasic course with focal neurological symptoms atypical for migraine aura makes HaNDL unique. Recognition of this uncommon syndrome is important and should be included in the differential diagnosis in a patient presenting with headache and focal neurological symptoms after viral illness including COVID-19. However, it remains important to exclude other potentially serious conditions presenting in a similar fashion.

Disclosures. S. Marzoughi reports no disclosures. A. Plecash reports no disclosures. T. Chen reports no disclosures.

Statement of authorship. SM: drafting/revision of the manuscript for content, including medical writing for content; analysis or interpretation of data.

AP: drafting/revision of the manuscript for content, including medical writing for content. TC: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept and design; analysis or interpretation of data.

References

1. Fernández-de-Las-Peñas C, Navarro-Santana M, Gómez-Mayordomo V, et al. Headache as an acute and post-COVID-19 symptom in COVID-19 survivors: A meta-analysis of the current literature. *Eur J Neurol*. 2021;28:3820–5. DOI [10.1111/ene.15040](https://doi.org/10.1111/ene.15040).
2. Balcom EF, Nath A, Power C. Acute and chronic neurological disorders in COVID-19: Potential mechanisms of disease. *Brain*. 2021;144:3576–88. DOI [10.1093/brain/awab302](https://doi.org/10.1093/brain/awab302).
3. García JCN, Isasi MTA, Parada M, et al. Síndrome de HaNDL tras infección por COVID-19. *Neurol Perspect*. 2022;2:253–5. DOI [10.1016/j.neurop.2022.06.007](https://doi.org/10.1016/j.neurop.2022.06.007).
4. Do TP, Remmers A, Schytz HW, et al. Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list. *Neurology*. 2019;92:134–44. DOI [10.1212/WNL.0000000000006697](https://doi.org/10.1212/WNL.0000000000006697).
5. Bartleson JD, Swanson JW, Whisnant JP. A migrainous syndrome with cerebrospinal fluid pleocytosis. *Neurology*. 1981;31:1257–62. DOI [10.1212/wnl.31.10.1257](https://doi.org/10.1212/wnl.31.10.1257).
6. Gómez-Aranda F, Cañadillas F, Martí-Massó JF, et al. Pseudomigraine with temporary neurological symptoms and lymphocytic pleocytosis. A report of 50 cases. *Brain*. 1997;120:1105–13. DOI [10.1093/brain/120.7.1105](https://doi.org/10.1093/brain/120.7.1105).
7. Kürtüncü M, Kaya D, Zuliani L, et al. CACNA1H antibodies associated with headache with neurological deficits and cerebrospinal fluid lymphocytosis (HaNDL). *Cephalalgia*. 2013;33:123–9. DOI [10.1177/0333102412463494](https://doi.org/10.1177/0333102412463494).
8. Fraunfelder FW, Fraunfelder FT, Corbett JJ. Isotretinoin-associated intracranial hypertension. *Ophthalmology*. 2004;111:1248–50. DOI [10.1016/j.optha.2003.09.044](https://doi.org/10.1016/j.optha.2003.09.044).
9. Barkana Y, Levin N, Goldhammer Y, Steiner I. Chronic intracranial hypertension with unexplained cerebrospinal fluid pleocytosis. *J Neuroophthalmol*. 2004;24:106–8. DOI [10.1097/00041327-200406000-00002](https://doi.org/10.1097/00041327-200406000-00002).
10. Silva MTT, Lima MA, Torezani G, et al. Isolated intracranial hypertension associated with COVID-19. *Cephalalgia*. 2020;40:1452–8. DOI [10.1177/0333102420965963](https://doi.org/10.1177/0333102420965963).
11. Garcia-Azorin D, Layos-Romero A, Porta-Etessam J, et al. Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients. *Cephalalgia*. 2022;42:804–9. DOI [10.1177/03331024211068074](https://doi.org/10.1177/03331024211068074).
12. Tana C, Bentivegna E, Cho SJ, et al. Long COVID headache. *J Headache Pain*. 2022;23:93. DOI [10.1186/s10194-022-01450-8](https://doi.org/10.1186/s10194-022-01450-8).